Report Detail

Request for Sample of this report

Pharma & Healthcare Global Chronic Metabolic Disease Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

  • RnM4743628
    • |
  • 28 September, 2026
    • |
  • Global
    • |
  • 117 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Chronic Metabolic Disease Drug market size was valued at US$ 63050 million in 2025 and is forecast to a readjusted size of US$ 103500 million by 2032 with a CAGR of 7.4% during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Chronic Metabolic Disease Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Chronic Metabolic Disease Drug market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
Global Chronic Metabolic Disease Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
Global Chronic Metabolic Disease Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
Global Chronic Metabolic Disease Drug market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/Ton), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Chronic Metabolic Disease Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Chronic Metabolic Disease Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Daiichi Sankyo, Actelion Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Fresenius Kabi, Torrent Labs, Pfizer, Novo Nordisk, AstraZeneca plc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Chronic Metabolic Disease Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Hypertension Drug
Hyperlipidemia Drug
High Blood Sugar Drug
High Uric Acid Drug
Market segment by Application
Hospital
Clinic
Others
Major players covered
Novartis
Daiichi Sankyo
Actelion Pharmaceuticals
Boehringer Ingelheim
Eli Lilly
Fresenius Kabi
Torrent Labs
Pfizer
Novo Nordisk
AstraZeneca plc
Regeneron Pharmaceuticals
GlaxoSmithKline plc
Merck & Co. Inc
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Chronic Metabolic Disease Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Chronic Metabolic Disease Drug, with price, sales quantity, revenue, and global market share of Chronic Metabolic Disease Drug from 2021 to 2026.
Chapter 3, the Chronic Metabolic Disease Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Chronic Metabolic Disease Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Chronic Metabolic Disease Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Chronic Metabolic Disease Drug.
Chapter 14 and 15, to describe Chronic Metabolic Disease Drug sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Chronic Metabolic Disease Drug Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Hypertension Drug
    • 1.3.3 Hyperlipidemia Drug
    • 1.3.4 High Blood Sugar Drug
    • 1.3.5 High Uric Acid Drug
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Chronic Metabolic Disease Drug Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Clinic
    • 1.4.4 Others
  • 1.5 Global Chronic Metabolic Disease Drug Market Size & Forecast
    • 1.5.1 Global Chronic Metabolic Disease Drug Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Chronic Metabolic Disease Drug Sales Quantity (2021-2032)
    • 1.5.3 Global Chronic Metabolic Disease Drug Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Novartis
    • 2.1.1 Novartis Details
    • 2.1.2 Novartis Major Business
    • 2.1.3 Novartis Chronic Metabolic Disease Drug Product and Services
    • 2.1.4 Novartis Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Novartis Recent Developments/Updates
  • 2.2 Daiichi Sankyo
    • 2.2.1 Daiichi Sankyo Details
    • 2.2.2 Daiichi Sankyo Major Business
    • 2.2.3 Daiichi Sankyo Chronic Metabolic Disease Drug Product and Services
    • 2.2.4 Daiichi Sankyo Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Daiichi Sankyo Recent Developments/Updates
  • 2.3 Actelion Pharmaceuticals
    • 2.3.1 Actelion Pharmaceuticals Details
    • 2.3.2 Actelion Pharmaceuticals Major Business
    • 2.3.3 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Product and Services
    • 2.3.4 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Actelion Pharmaceuticals Recent Developments/Updates
  • 2.4 Boehringer Ingelheim
    • 2.4.1 Boehringer Ingelheim Details
    • 2.4.2 Boehringer Ingelheim Major Business
    • 2.4.3 Boehringer Ingelheim Chronic Metabolic Disease Drug Product and Services
    • 2.4.4 Boehringer Ingelheim Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Boehringer Ingelheim Recent Developments/Updates
  • 2.5 Eli Lilly
    • 2.5.1 Eli Lilly Details
    • 2.5.2 Eli Lilly Major Business
    • 2.5.3 Eli Lilly Chronic Metabolic Disease Drug Product and Services
    • 2.5.4 Eli Lilly Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Eli Lilly Recent Developments/Updates
  • 2.6 Fresenius Kabi
    • 2.6.1 Fresenius Kabi Details
    • 2.6.2 Fresenius Kabi Major Business
    • 2.6.3 Fresenius Kabi Chronic Metabolic Disease Drug Product and Services
    • 2.6.4 Fresenius Kabi Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Fresenius Kabi Recent Developments/Updates
  • 2.7 Torrent Labs
    • 2.7.1 Torrent Labs Details
    • 2.7.2 Torrent Labs Major Business
    • 2.7.3 Torrent Labs Chronic Metabolic Disease Drug Product and Services
    • 2.7.4 Torrent Labs Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Torrent Labs Recent Developments/Updates
  • 2.8 Pfizer
    • 2.8.1 Pfizer Details
    • 2.8.2 Pfizer Major Business
    • 2.8.3 Pfizer Chronic Metabolic Disease Drug Product and Services
    • 2.8.4 Pfizer Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Pfizer Recent Developments/Updates
  • 2.9 Novo Nordisk
    • 2.9.1 Novo Nordisk Details
    • 2.9.2 Novo Nordisk Major Business
    • 2.9.3 Novo Nordisk Chronic Metabolic Disease Drug Product and Services
    • 2.9.4 Novo Nordisk Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Novo Nordisk Recent Developments/Updates
  • 2.10 AstraZeneca plc
    • 2.10.1 AstraZeneca plc Details
    • 2.10.2 AstraZeneca plc Major Business
    • 2.10.3 AstraZeneca plc Chronic Metabolic Disease Drug Product and Services
    • 2.10.4 AstraZeneca plc Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 AstraZeneca plc Recent Developments/Updates
  • 2.11 Regeneron Pharmaceuticals
    • 2.11.1 Regeneron Pharmaceuticals Details
    • 2.11.2 Regeneron Pharmaceuticals Major Business
    • 2.11.3 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Product and Services
    • 2.11.4 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Regeneron Pharmaceuticals Recent Developments/Updates
  • 2.12 GlaxoSmithKline plc
    • 2.12.1 GlaxoSmithKline plc Details
    • 2.12.2 GlaxoSmithKline plc Major Business
    • 2.12.3 GlaxoSmithKline plc Chronic Metabolic Disease Drug Product and Services
    • 2.12.4 GlaxoSmithKline plc Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 GlaxoSmithKline plc Recent Developments/Updates
  • 2.13 Merck & Co. Inc
    • 2.13.1 Merck & Co. Inc Details
    • 2.13.2 Merck & Co. Inc Major Business
    • 2.13.3 Merck & Co. Inc Chronic Metabolic Disease Drug Product and Services
    • 2.13.4 Merck & Co. Inc Chronic Metabolic Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Merck & Co. Inc Recent Developments/Updates

3 Competitive Environment: Chronic Metabolic Disease Drug by Manufacturer

  • 3.1 Global Chronic Metabolic Disease Drug Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Chronic Metabolic Disease Drug Revenue by Manufacturer (2021-2026)
  • 3.3 Global Chronic Metabolic Disease Drug Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Chronic Metabolic Disease Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Chronic Metabolic Disease Drug Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Chronic Metabolic Disease Drug Manufacturer Market Share in 2025
  • 3.5 Chronic Metabolic Disease Drug Market: Overall Company Footprint Analysis
    • 3.5.1 Chronic Metabolic Disease Drug Market: Region Footprint
    • 3.5.2 Chronic Metabolic Disease Drug Market: Company Product Type Footprint
    • 3.5.3 Chronic Metabolic Disease Drug Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Chronic Metabolic Disease Drug Market Size by Region
    • 4.1.1 Global Chronic Metabolic Disease Drug Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Chronic Metabolic Disease Drug Consumption Value by Region (2021-2032)
    • 4.1.3 Global Chronic Metabolic Disease Drug Average Price by Region (2021-2032)
  • 4.2 North America Chronic Metabolic Disease Drug Consumption Value (2021-2032)
  • 4.3 Europe Chronic Metabolic Disease Drug Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Chronic Metabolic Disease Drug Consumption Value (2021-2032)
  • 4.5 South America Chronic Metabolic Disease Drug Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Chronic Metabolic Disease Drug Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Chronic Metabolic Disease Drug Sales Quantity by Type (2021-2032)
  • 5.2 Global Chronic Metabolic Disease Drug Consumption Value by Type (2021-2032)
  • 5.3 Global Chronic Metabolic Disease Drug Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Chronic Metabolic Disease Drug Sales Quantity by Application (2021-2032)
  • 6.2 Global Chronic Metabolic Disease Drug Consumption Value by Application (2021-2032)
  • 6.3 Global Chronic Metabolic Disease Drug Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Chronic Metabolic Disease Drug Sales Quantity by Type (2021-2032)
  • 7.2 North America Chronic Metabolic Disease Drug Sales Quantity by Application (2021-2032)
  • 7.3 North America Chronic Metabolic Disease Drug Market Size by Country
    • 7.3.1 North America Chronic Metabolic Disease Drug Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Chronic Metabolic Disease Drug Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Chronic Metabolic Disease Drug Sales Quantity by Type (2021-2032)
  • 8.2 Europe Chronic Metabolic Disease Drug Sales Quantity by Application (2021-2032)
  • 8.3 Europe Chronic Metabolic Disease Drug Market Size by Country
    • 8.3.1 Europe Chronic Metabolic Disease Drug Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Chronic Metabolic Disease Drug Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Chronic Metabolic Disease Drug Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Chronic Metabolic Disease Drug Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Chronic Metabolic Disease Drug Market Size by Region
    • 9.3.1 Asia-Pacific Chronic Metabolic Disease Drug Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Chronic Metabolic Disease Drug Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Chronic Metabolic Disease Drug Sales Quantity by Type (2021-2032)
  • 10.2 South America Chronic Metabolic Disease Drug Sales Quantity by Application (2021-2032)
  • 10.3 South America Chronic Metabolic Disease Drug Market Size by Country
    • 10.3.1 South America Chronic Metabolic Disease Drug Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Chronic Metabolic Disease Drug Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Chronic Metabolic Disease Drug Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Chronic Metabolic Disease Drug Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Chronic Metabolic Disease Drug Market Size by Country
    • 11.3.1 Middle East & Africa Chronic Metabolic Disease Drug Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Chronic Metabolic Disease Drug Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Chronic Metabolic Disease Drug Market Drivers
  • 12.2 Chronic Metabolic Disease Drug Market Restraints
  • 12.3 Chronic Metabolic Disease Drug Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Chronic Metabolic Disease Drug and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Chronic Metabolic Disease Drug
  • 13.3 Chronic Metabolic Disease Drug Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Chronic Metabolic Disease Drug Typical Distributors
  • 14.3 Chronic Metabolic Disease Drug Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Chronic Metabolic Disease Drug. Industry analysis & Market Report on Chronic Metabolic Disease Drug is a syndicated market report, published as Global Chronic Metabolic Disease Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Chronic Metabolic Disease Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo